Neurological Disease After Mold Exposure, Immune Risks & Response to Biofilm-Focused Antifungal Therapy

Ref ID: 18671


J. F. Rini, MS – ., I. H. Grant, MD (Doctor of Medicine) – Clinical Assistant Professor, Department of Family and Community Medicine;

Author address:

New York Med. Coll., Valhalla, NY

Full conference title:

52nd Annual ICAAC

Date: 9 September 2014


Background: Stachybotrys (St) and Aspergillus-Penicillium (Asp-Pen) biofilm products may cause symptoms (sxs) without invasion. Amphotericin B (Ampho), the only mold biofilm-eradicating antifungal, cannot cross tissues. Since mold toxins may cause neurological (neuro) sxs, upper-respiratory/GI biofilm-focused antifungal therapy (Rx) was studied, correlating neuro sxs with immune risks, antibodies (AB’s), urine mycotoxins (MCT’s) and Rx response. Methods: Monitored 25 patients with neuro sxs after proven mold exposure (11M,14F,age 27-91) for immune risks, specific AB’s, urine MCT’s and response to oral-nasal Ampho +/- systemic azoles or capsofungin. Results: Debility paralled exposure intensity, impaired immunity, or multiple MCT’s.Response to RX was striking with 21/23 (91%) unequivocally improved, most in 1-3 months. Penetration markers(adenopathy, nodules, calcification) required prolonged(>1 year)relapsing with interruptions. Conclusion: Since Stachybotrys & Aspergillus-Penicillium exposure can result in neuro sxs that dramatically reverse with combined biofilm-focused/systemic antifungals, such sxs may result from toxin mediated fungal disease and should trigger mold exposure inquiry and screening for immune defects, quantitative mold IgG and mycotoxins. Controlled clinical antifungal trials are needed.

Abstract Number: M-1063

Conference Year: 2012

Link to conference website: NULL

New link:

Conference abstracts, posters & presentations

Showing 10 posts of 17225 posts found.
  • Title





Our sponsors